Literature DB >> 8862378

Population-based analysis of treatment of pancreatic cancer and Whipple resection: Department of Defense hospitals, 1989-1994.

T P Wade1, I A Halaby, D R Stapleton, K S Virgo, F E Johnson.   

Abstract

BACKGROUND: The influence of hospital experience and referral patterns on the operative mortality rate of pancreaticoduodenectomy was studied in a worldwide hospital system.
METHODS: We analyzed computerized data on pancreatic cancer patients from U.S. Department of Defense (DOD) hospitals from 1989 to 1994.
RESULTS: Six hundred ninety-eight patients had pancreatic cancer, and 130 Whipple operations (105 for pancreatic and 25 for other cancers) were performed with an 8.5% 30-day operative mortality rate. Although most resections were done in teaching hospitals performing more than 1 Whipple procedure per year, their results were not superior to smaller, lower volume nonteaching hospitals. Patients transported for resection were younger than patients undergoing resection at their local DOD hospital but had similar outcomes. The operative mortality rate was higher after unusual resections and with increasing age; the tumor stage had no effect. Unresected patients undergoing combined radiation and chemotherapy had the longest survival times. Radiation therapy was associated with significantly longer survival times in patients without distant metastases, but chemotherapy was associated with a longer survival time when metastases were present.
CONCLUSIONS: This mortality rate 8.5% for Whipple resections matches that from other large populations. Equivalent results were obtained in DOD teaching hospitals and smaller, community-type institutions. Because the DOD medical system minimizes financial and logistic barriers to transfer, the even distribution of DOD pancreatectomy mortality suggests that these barriers may favorably influence single institutional outcomes.

Entities:  

Mesh:

Year:  1996        PMID: 8862378     DOI: 10.1016/s0039-6060(96)80017-1

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  15 in total

Review 1.  Adjuvant therapy in pancreatic cancer.

Authors:  P Ghaneh; J Slavin; R Sutton; M Hartley; J P Neoptolemos
Journal:  World J Gastroenterol       Date:  2001-08       Impact factor: 5.742

2.  Relation between hospital surgical volume and outcome for pancreatic resection for neoplasm in a publicly funded health care system.

Authors:  M Simunovic; T To; M Theriault; B Langer
Journal:  CMAJ       Date:  1999-03-09       Impact factor: 8.262

3.  More procedures, better quality of care? Is there a case for regionalization of pancreatic resection for neoplasm?

Authors:  M J Wexler
Journal:  CMAJ       Date:  1999-03-09       Impact factor: 8.262

4.  The volume-outcome relationship in cancer surgery: a hard sell.

Authors:  Ingemar Ihse
Journal:  Ann Surg       Date:  2003-12       Impact factor: 12.969

Review 5.  Hospital volume and mortality after pancreatic resection: a systematic review and an evaluation of intervention in the Netherlands.

Authors:  N Tjarda van Heek; Koert F D Kuhlmann; Rob J Scholten; Steve M M de Castro; Olivier R C Busch; Thomas M van Gulik; Huug Obertop; Dirk J Gouma
Journal:  Ann Surg       Date:  2005-12       Impact factor: 12.969

6.  The association between higher volume and better outcome for pancreatoduodenectomy.

Authors:  I Ihse
Journal:  HPB (Oxford)       Date:  2001       Impact factor: 3.647

7.  Perductal electrolytic ablation of the porcine pancreas: a minimally invasive option-studies of morbidity and mortality.

Authors:  C P Morrison; F G Court; S A Wemyss-Holden; B D Teague; A Burrell; M Texler; M S Metcalfe; A R Dennison; G J Maddern
Journal:  Surg Endosc       Date:  2004-08-24       Impact factor: 4.584

8.  Type and case volume of health care facility influences survival and surgery selection in cases with early-stage non-small cell lung cancer.

Authors:  Shidan Wang; Sunny Lai; Mitchell S von Itzstein; Lin Yang; Donghan M Yang; Xiaowei Zhan; Guanghua Xiao; Ethan A Halm; David E Gerber; Yang Xie
Journal:  Cancer       Date:  2019-09-10       Impact factor: 6.860

9.  Does neoadjuvant chemoradiation downstage locally advanced pancreatic cancer?

Authors:  Hong Jin Kim; Karen Czischke; Murray F Brennan; Kevin C Conlon
Journal:  J Gastrointest Surg       Date:  2002 Sep-Oct       Impact factor: 3.452

10.  Periampullary adenocarcinoma: analysis of 5-year survivors.

Authors:  C J Yeo; T A Sohn; J L Cameron; R H Hruban; K D Lillemoe; H A Pitt
Journal:  Ann Surg       Date:  1998-06       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.